Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.45 |
| ▸ | SCARB1 | Q8WTV0 | 11/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17669672 | 0.87 | MAPK14 (0.49) | MAPK14SCARB1BRAF | |
| SCHEMBL17652877 | 0.83 | MAPK14 (0.46) | MAPK14SCARB1 | |
| SCHEMBL1846611 | 0.81 | MAPK14 (0.63) | MAPK14SCARB1BRAF | |
| SCHEMBL17652970 | 0.77 | HTT (0.41) | MAPK14SCARB1 | |
| SCHEMBL20541046 | 0.75 | MAPK14 (0.42) | MAPK14SCARB1 | |
| SCHEMBL16829205 | 0.75 | MAPK14 (0.47) | MAPK14SCARB1BRAFSRCSYK | |
| SCHEMBL16106451 | 0.75 | MAPK14 (0.50) | MAPK14SRCSYK | |
| SCHEMBL22705390 | 0.74 | MAPK14 (0.46) | MAPK14SCARB1 | |
| SCHEMBL16829249 | 0.73 | MAPK14 (0.50) | MAPK14SCARB1BRAFSRCSYK | |
| SCHEMBL19434576 | 0.73 | MAPK14 (0.54) | MAPK14SCARB1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941115-B2 | Kinase inhibitors | OXULAR ACQUISITIONS LIMITED (GB) | 2021-03-09 | — | — | US | disclosed |
| US-20190330155-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2019-10-31 | — | — | US | disclosed |
| US-10392346-B2 | Kinase inhibitors | TOPIVERT PHARMA LIMITED (GB) | 2019-08-27 | — | — | US | disclosed |
| US-10125100-B2 | Kinase inhibitors | RESPIVERT LIMITED | 2018-11-13 | — | — | US | disclosed |
| US-20180319748-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2018-11-08 | — | — | US | disclosed |
| US-20170253563-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| US-9751837-B2 | Kinase inhibitors | RESPIVERT LIMITED (GB) | 2017-09-05 | — | — | US | disclosed |
| US-20160102059-A1 | KINASE INHIBITORS | OXULAR ACQUISITIONS LIMITED (GB) | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319748-A1 | KINASE INHIBITORS | LYN, SYK, BTK | MAPK14 96/4885SCARB1 567/4885BRAF 157/4885 |
| US-10125100-B2 | Kinase inhibitors | SYK, LYN, SRC | MAPK14 103/4885SCARB1 744/4885BRAF 101/4885 |
| US-20190330155-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK14 118/4885SCARB1 786/4885BRAF 109/4885 |
| US-10941115-B2 | Kinase inhibitors | SYK, LYN, BTK | MAPK14 118/4885SCARB1 786/4885BRAF 109/4885 |
| US-20160102059-A1 | KINASE INHIBITORS | SYK, LYN, BTK | MAPK14 120/4885SCARB1 750/4885BRAF 114/4885 |
| US-20170253563-A1 | KINASE INHIBITORS | SYK, LYN, SRC | MAPK14 103/4885SCARB1 744/4885BRAF 101/4885 |
| US-10392346-B2 | Kinase inhibitors | LYN, SYK, BTK | MAPK14 96/4885SCARB1 567/4885BRAF 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.